Cite
HARVARD Citation
Lin, C. et al. (n.d.). Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC). European journal of cancer. pp. S12-S13. [Online].